Pfizer EBITDA Margin 2010-2023 | PFE
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Pfizer (PFE) over the last 10 years. The current EBITDA margin for Pfizer as of December 31, 2023 is .
| Pfizer EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-12-31 |
$58.50B |
$6.51B |
11.13% |
| 2023-09-30 |
$68.54B |
$15.35B |
22.40% |
| 2023-06-30 |
$77.94B |
$27.35B |
35.09% |
| 2023-03-31 |
$92.95B |
$37.25B |
40.07% |
| 2022-12-31 |
$100.33B |
$40.01B |
39.88% |
| 2022-09-30 |
$99.88B |
$38.43B |
38.48% |
| 2022-06-30 |
$101.28B |
$35.80B |
35.34% |
| 2022-03-31 |
$92.43B |
$29.32B |
31.72% |
| 2021-12-31 |
$81.29B |
$24.62B |
30.29% |
| 2021-09-30 |
$68.88B |
$22.11B |
32.10% |
| 2021-06-30 |
$55.12B |
$18.28B |
33.16% |
| 2021-03-31 |
$46.08B |
$14.63B |
31.76% |
| 2020-12-31 |
$41.65B |
$12.93B |
31.05% |
| 2020-09-30 |
$32.07B |
$7.32B |
22.83% |
| 2020-06-30 |
$34.47B |
$8.18B |
23.72% |
| 2020-03-31 |
$37.87B |
$10.70B |
28.25% |
| 2019-12-31 |
$40.91B |
$12.47B |
30.47% |
| 2019-09-30 |
$40.22B |
$11.65B |
28.98% |
| 2019-06-30 |
$40.84B |
$12.52B |
30.66% |
| 2019-03-31 |
$41.04B |
$12.27B |
29.89% |
| 2018-12-31 |
$40.83B |
$11.82B |
28.96% |
| 2018-09-30 |
$53.37B |
$20.31B |
38.06% |
| 2018-06-30 |
$53.24B |
$20.17B |
37.87% |
| 2018-03-31 |
$52.67B |
$19.94B |
37.86% |
| 2017-12-31 |
$52.55B |
$19.99B |
38.04% |
| 2017-09-30 |
$52.47B |
$19.42B |
37.00% |
| 2017-06-30 |
$52.35B |
$18.60B |
35.54% |
| 2017-03-31 |
$52.60B |
$18.15B |
34.51% |
| 2016-12-31 |
$52.82B |
$17.90B |
33.89% |
| 2016-09-30 |
$53.24B |
$17.86B |
33.53% |
| 2016-06-30 |
$52.29B |
$18.07B |
34.56% |
| 2016-03-31 |
$50.99B |
$18.00B |
35.30% |
| 2015-12-31 |
$48.85B |
$16.98B |
34.76% |
| 2015-09-30 |
$47.92B |
$17.20B |
35.89% |
| 2015-06-30 |
$48.20B |
$17.58B |
36.47% |
| 2015-03-31 |
$49.12B |
$18.16B |
36.97% |
| 2014-12-31 |
$49.61B |
$18.79B |
37.87% |
| 2014-09-30 |
$50.05B |
$19.84B |
39.64% |
| 2014-06-30 |
$50.33B |
$20.34B |
40.41% |
| 2014-03-31 |
$50.53B |
$20.88B |
41.32% |
| 2013-12-31 |
$51.58B |
$21.59B |
41.86% |
| 2013-09-30 |
$50.88B |
$21.73B |
42.71% |
| 2013-06-30 |
$51.19B |
$21.62B |
42.24% |
| 2013-03-31 |
$52.18B |
$22.25B |
42.64% |
| 2012-12-31 |
$54.66B |
$22.92B |
41.93% |
| 2012-09-30 |
$53.25B |
$22.62B |
42.49% |
| 2012-06-30 |
$56.90B |
$23.53B |
41.35% |
| 2012-03-31 |
$59.42B |
$23.26B |
39.14% |
| 2011-12-31 |
$61.04B |
$22.99B |
37.67% |
| 2011-09-30 |
$65.06B |
$22.42B |
34.45% |
| 2011-06-30 |
$64.44B |
$22.10B |
34.30% |
| 2011-03-31 |
$65.09B |
$22.25B |
34.18% |
| 2010-12-31 |
$65.17B |
$21.81B |
33.47% |
| 2010-09-30 |
$65.50B |
$19.75B |
30.16% |
| 2010-06-30 |
$61.13B |
$18.86B |
30.86% |
| 2010-03-31 |
$54.98B |
$16.57B |
30.15% |
| 2009-12-31 |
$49.27B |
$15.72B |
31.90% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.755B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
